Literature DB >> 20128028

Phlebotomy improves histology in chronic hepatitis C males with mild iron overload.

Massimo Sartori1, Silvano Andorno, Angelo Rossini, Renzo Boldorini, Cristina Bozzola, Stefania Carmagnola, Mario Del Piano, Emanuele Albano.   

Abstract

AIM: To investigate the usefulness of mild iron depletion and the factors predictive for histological improvement following phlebotomy in Caucasians with chronic hepatitis C (CHC).
METHODS: We investigated 28 CHC Caucasians with persistently elevated serum aminotransferase levels and non responders to, or unsuitable for, antiviral therapy who underwent mild iron depletion (ferritin < or = 70 ng/mL) by long-term phlebotomy. Histological improvement, as defined by at least one point reduction in the staging score or, in case of unchanged stage, as at least two points reduction in the grading score (Knodell), was evaluated in two subsequent liver biopsies (before and at the end of phlebotomy, 48 +/- 16 mo apart).
RESULTS: Phlebotomy showed an excellent safety profile. Histological improvement occurred in 12/28 phlebotomized patients. Only males responded to phlebotomy. At univariate logistic analysis alcohol intake (P = 0.034), high histological grading (P = 0.01) and high hepatic iron concentration (HIC) (P = 0.04) before treatment were associated with histological improvement. Multivariate logistic analysis showed that in males high HIC was the only predictor of histological improvement following phlebotomy (OR = 1.41, 95% CI: 1.03-1.94, P = 0.031). Accordingly, 12 out of 17 (70%) patients with HIC > or = 20 micromol/g showed histological improvements at the second biopsy.
CONCLUSION: Male CHC Caucasian non-responders to antiviral therapy with low-grade iron overload can benefit from mild iron depletion by long-term phlebotomy.

Entities:  

Mesh:

Year:  2010        PMID: 20128028      PMCID: PMC2816272          DOI: 10.3748/wjg.v16.i5.596

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.

Authors:  Motoyoshi Yano; Hisao Hayashi; Shinya Wakusawa; Fujiko Sanae; Toshikuni Takikawa; Yuhta Shiono; Motohiro Arao; Koji Ukai; Hiroshi Ito; Kazumasa Watanabe; Kentaro Yoshioka
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

Review 2.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 3.  Hemochromatosis gene modifies course of hepatitis C viral infection.

Authors:  Antonello Pietrangelo
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

4.  Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.

Authors:  J Kato; M Kobune; T Nakamura; G Kuroiwa; K Takada; R Takimoto; Y Sato; K Fujikawa; M Takahashi; T Takayama; T Ikeda; Y Niitsu
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 5.  Optimal therapy of hepatitis C.

Authors:  Adrian M Di Bisceglie; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

6.  Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C.

Authors:  Massimo Sartori; Silvano Andorno; Michela Pagliarulo; Cristina Rigamonti; Cristina Bozzola; Patrizia Pergolini; Roberta Rolla; Anna Suno; Renzo Boldorini; Giorgio Bellomo; Emanuele Albano
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

7.  Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.

Authors:  A M Di Bisceglie; H L Bonkovsky; S Chopra; S Flamm; R K Reddy; N Grace; P Killenberg; C Hunt; C Tamburro; A S Tavill; R Ferguson; E Krawitt; B Banner; B R Bacon
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

Review 8.  Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

Authors:  M Simin; J Brok; D Stimac; C Gluud; L L Gluud
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

9.  A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.

Authors:  Motoyoshi Yano; Hisao Hayashi; Kentaro Yoshioka; Yutaka Kohgo; Hiroyuki Saito; Yoshiro Niitsu; Junji Kato; Shiro Iino; Hiroshi Yotsuyanagi; Yoshimasa Kobayashi; Kinya Kawamura; Shinichi Kakumu; Masahiko Kaito; Jiro Ikoma; Shinya Wakusawa; Takeshi Okanoue; Yoshio Sumida; Fumiaki Kimura; Eiji Kajiwara; Michio Sata; Kei Ogata
Journal:  J Gastroenterol       Date:  2004-06       Impact factor: 7.527

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  3 in total

1.  Serum ferritin and the risk of hepatocellular carcinoma in chronic liver disease of viral etiology: a case-control study.

Authors:  Prachi S Patil; K M Mohandas; Shobna J Bhatia; Shaesta A Mehta
Journal:  Indian J Gastroenterol       Date:  2013-09-05

2.  Gender difference of alanine aminotransferase elevation may be associated with higher hemoglobin levels among male adolescents.

Authors:  Solomon Chih-Cheng Chen; Jun-Jun Yeh; Mei-Hwei Chang; Yu-Kuei Liao; Li-Chen Hsiao; Choo-Aun Neoh; Teck-Siang Tok; Jung-Der Wang
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 3.  Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk.

Authors:  Gerald Koenig; Stephanie Seneff
Journal:  Dis Markers       Date:  2015-10-12       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.